Deek, M. P., Shi, X., Radwan, N., Eggleston, C., Baker, K., Rana, Z. H., Ferris, M. J., Kwok, Y., Bentzen, S., Ennis, R. D., Hathout, L., Saraiya, B., Mayer, T. M., Mannuel, H. D., Hussain, A., Abramowitz, M., Berlin, A., Mishra, M. V., Tran, P. T., Molitoris, J. K. (2025). Phase 2 randomized study of high-risk metachronous oligometastatic prostate cancer with high-risk mutations treated with metastasis-directed therapy and niraparib/abiraterone acetate plus prednisone (KNIGHTS) trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps283